Jacobs Levy Equity Management Inc. Purchases Shares of 24,921 Thermo Fisher Scientific Inc. $TMO

Key Points

• Jacobs Levy Equity Management Inc. acquired 24,921 shares of Thermo Fisher Scientific Inc. valued at approximately $12.4 million, highlighting increased institutional investment in the medical research company.
• Several hedge funds have raised their positions in Thermo Fisher, with the stock currently 89.23% owned by institutional investors, indicating strong market confidence.
• Analysts have set a consensus rating of "Moderate Buy" for Thermo Fisher, with price targets ranging from $480 to $589.38, suggesting potential growth in the stock.

Jacobs Levy Equity Management Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 24,921 shares of the medical research company's stock, valued at approximately $12,401,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Amundi increased its stake in shares of Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after purchasing an additional 168,197 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA grew its stake in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after buying an additional 193,378 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock valued at $1,259,450,000 after buying an additional 257,462 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $9.09 on Friday, reaching $482.32. 529,876 shares of the stock were exchanged, compared to its average volume of 2,392,841. The firm's 50 day moving average is $465.84 and its 200-day moving average is $452.06. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $182.13 billion, a PE ratio of 27.87, a P/E/G ratio of 2.54 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 EPS. The firm's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on TMO. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. HSBC reiterated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Seventeen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.